In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1651-1657

  Jones, Mark E ^a   Critchley, Ian A ^a   Karlowsky, James A ^a   Blosser Middleton, Renée S ^a   Schmitz, Franz Josef ^a   Thornsberry, Clyde ^a   Sahm, Daniel F ^a  

^a Focus Technologies   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; GATIFLOXACIN; GENE PRODUCT; LEVOFLOXACIN; MOXIFLOXACIN; PGE 9262932; PGE 9509924; PROTEIN GRLA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; GENE MUTATION; GENE SEQUENCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036095939     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1651-1657.2002     Document Type: Article

References (24)

1. In vitro activities of three nonfluorinated quinolones against representative bacterial species
2. 6-Aminoquinolones as new potential anti-HIV agents
3. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone
4. Primary targets of fluoroquinolones in Streptococcus pneumoniae Antimicrob
5. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
6. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
7. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
8. A prevalence study of gyrA, gyrB, parC, and pare mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
9. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae
10. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
11. Quinolone resistance mediated by norA: Physiological characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome
12. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
13. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
14. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
15. Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity
16. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
17. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae
18. Quinolone resistance in staphylococci: Activities of the new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates
19. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MICs
20. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: Involvement of multiple mutations in gyrA and parC genes
21. Mutations in gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus
22. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro